Improving Scalability of AAV and Lentivirus Production: Tailored Transfection Reagents Enable Large-Scale Manufacturing

Miguel Dominguez

December 15, 2022

1 Min Read

20-11-12-CR-Mirus-Cover-Border-222x300.pngScientific advances have increased the safety and efficacy of recombinant viral-vector technology for cell and gene therapies. In this special report, we will discuss how tailored transfection reagents improve the scalability of AAV and lentivirus production. We will also focus on the challenges of scaling up viral vector production platforms and the importance of selecting the right transfection reagent for this process to increase the titer and quality of viral production to generate more therapeutic doses per run.

Fill out the form below to read the full report from Mirus Bio.

You May Also Like